Reduced membranous MET expression is linked to bladder cancer progression

Cancer Genetics

Volumn 207, Issue 4, 2014, Pages 147-152

  Kluth, Martina ^a   Reynolds, Kristina ^a   Rink, Michael ^a   Chun, Felix ^a   Dahlem, Roland ^a   Fisch, Margit ^a   Höppner, Wolfgang ^b   Wagner, Walter ^c   Doh, Ousman ^d   Terracciano, Luigi ^e   Simon, Ronald ^a   Sauter, Guido ^a   Minner, Sarah ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b Clinical Center Itzehoe   (Germany)

^c Bundeswehrkrankenhaus Hamburg   (Germany)

^d Regio Klinik Wedel   (Germany)

^e UNIVERSITY OF BASEL   (Switzerland)

Author keywords

Bladder cancer; Immunohistochemistry; MET; Prognosis; Tissue microarray

Indexed keywords

SCATTER FACTOR RECEPTOR;

ARTICLE; BLADDER CANCER; CANCER GRADING; CANCER GROWTH; CANCER SPECIFIC SURVIVAL; CONTROLLED STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MET GENE; MOLECULAR PATHOLOGY; OVERALL SURVIVAL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE MICROARRAY;

BLADDER CANCER; IMMUNOHISTOCHEMISTRY; MET; PROGNOSIS; TISSUE MICROARRAY;

DISEASE PROGRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; KAPLAN-MEIER ESTIMATE; MEMBRANE PROTEINS; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MET; TISSUE ARRAY ANALYSIS; URINARY BLADDER NEOPLASMS;

EID: 84901623540     PISSN: 22107762     EISSN: 22107770     Source Type: Journal    
DOI: 10.1016/j.cancergen.2014.03.008     Document Type: Article

References (44)

1. Jemal A., Bray F., Center M.M., et al. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
2. Quek M.L., Quinn D.I., Daneshmand S., et al. Molecular prognostication in bladder cancer-a current perspective. Eur J Cancer 2003, 39:1501-1510.
3. Buscarini M., Quek M.L., Gill P., et al. Molecular prognostic factors in bladder cancer. BJU Int 2005, 95:739-742.
4. Rink M., Cha E.K., Green D., et al. Biomolecular predictors of urothelial cancer behavior and treatment outcomes. Curr Urol Rep 2012, 13:122-135.
5. Pusztai L., Lewis C.E., Lorenzen J., et al. Growth factors: regulation of normal and neoplastic growth. JPathol 1993, 169:191-201.
6. Brinkmann V., Foroutan H., Sachs M., et al. Hepatocyte growth factor/scatter factor induces a variety of tissue-specific morphogenic programs in epithelial cells. JCell Biol 1995, 131:1573-1586.
7. Birchmeier C., Birchmeier W., Gherardi E., et al. Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003, 4:915-925.
8. Gastaldi S., Comoglio P.M., Trusolino L. The Met oncogene and basal-like breast cancer: another culprit to watch out for?. Breast Cancer Res 2010, 12:208.
9. Graziano F., Galluccio N., Lorenzini P., et al. Genetic activation of the MET pathway and prognosis of patients with high-risk, radically resected gastric cancer. JClin Oncol 2011, 29:4789-4795.
10. De Oliveira A.T., Matos D., Logullo A.F., et al. MET is highly expressed in advanced stages of colorectal cancer and indicates worse prognosis and mortality. Anticancer Res 2009, 29:4807-4811.
11. Cheng H.L., Trink B., Tzai T.S., et al. Overexpression of c-met as a prognostic indicator for transitional cell carcinoma of the urinary bladder: a comparison with p53 nuclear accumulation. JClin Oncol 2002, 20:1544-1550.
12. Cheng H.L., Liu H.S., Lin Y.J., et al. Co-expression of RON and MET is a prognostic indicator for patients with transitional-cell carcinoma of the bladder. Br J Cancer 2005, 92:1906-1914.
13. Goetsch L., Caussanel V. Selection criteria for c-Met-targeted therapies: emerging evidence for biomarkers. Biomark Med 2010, 4:149-170.
14. Di Renzo M.F., Olivero M., Ferro S., et al. Overexpression of the c-MET/HGF receptor gene in human thyroid carcinomas. Oncogene 1992, 7:2549-2553.
15. Houldsworth J., Cordon-Cardo C., Ladanyi M., et al. Gene amplification in gastric and esophageal adenocarcinomas. Cancer Res 1990, 50:6417-6422.
16. Schmidt L., Duh F.M., Chen F., et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 1997, 16:68-73.
17. Lee J.H., Han S.U., Cho H., et al. Anovel germ line juxtamembrane Met mutation in human gastric cancer. Oncogene 2000, 19:4947-4953.
18. Park W.S., Dong S.M., Kim S.Y., et al. Somatic mutations in the kinase domain of the Met/hepatocyte growth factor receptor gene in childhood hepatocellular carcinomas. Cancer Res 1999, 59:307-310.
19. Di Renzo M.F., Olivero M., Martone T., et al. Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas. Oncogene 2000, 19:1547-1555.
20. Koochekpour S., Jeffers M., Rulong S., et al. Met and hepatocyte growth factor/scatter factor expression in human gliomas. Cancer Res 1997, 57:5391-5398.
21. Koga F., Tsutsumi S., Neckers L.M. Low dose geldanamycin inhibits hepatocyte growth factor and hypoxia-stimulated invasion of cancer cells. Cell Cycle 2007, 6:1393-1402.
22. Karkoulis P.K., Stravopodis D.J., Margaritis L.H., et al. 17-Allylamino-17-demethoxygeldanamycin induces downregulation of critical Hsp90 protein clients and results in cell cycle arrest and apoptosis of human urinary bladder cancer cells. BMC Cancer 2012, 10:481.
23. Todeschini A.R., Dos Santos J.N., Handa K., et al. Ganglioside GM2/GM3 complex affixed on silica nanospheres strongly inhibits cell motility through CD82/cMet-mediated pathway. Proc Natl Acad Sci USA 2008, 105:1925-1930.
24. Sanchez-Carbayo M., Socci N.D., Lozano J.J., et al. Profiling bladder cancer using targeted antibody arrays. Am J Pathol 2006, 168:93-103.
25. Joseph A., Weiss G.H., Jin L., et al. Expression of scatter factor in human bladder carcinoma. JNatl Cancer Inst 1995, 87:372-377.
26. Miyata Y., Sagara Y., Kanda S., et al. Phosphorylated hepatocyte growth factor receptor/c-Met is associated with tumor growth and prognosis in patients with bladder cancer: correlation with matrix metalloproteinase-2 and -7 and E-cadherin. Hum Pathol 2009, 40:496-504.
27. Wu T.F., Wu H., Wang Y.W., et al. Prohibitin in the pathogenesis oftransitional cell bladder cancer. Anticancer Res 2007, 27:895-900.
28. Wild P.J., Kunz-Schughart L.A., Stoehr R., et al. High-throughput tissue microarray analysis of COX2 expression in urinary bladder cancer. Int J Oncol 2005, 27:385-391.
29. Bubendorf L. High-throughput microarray technologies: from genomics to clinics. Eur Urol 2001, 40:231-238.
30. Mostofi F., Sobin L., Torloni H. Histological typing of urinary bladder tumours. International classification of tumours 1973, World Health Organization, Geneva.
31. TNM Classification of malignant tumors 1992, Union for International Cancer Control (UICC), Springer, Berlin. 4th ed.
32. Dancau A.M., Simon R., Mirlacher M., et al. Tissue microarrays. Methods Mol Biol 2010, 576:49-60.
33. Marx A.H., Zielinski M., Kowitz C.M., et al. Homogeneous EGFR amplification defines a subset of aggressive Barrett's adenocarcinomas with poor prognosis. Histopathology 2010, 57:418-426.
34. Yeh C.Y., Shin S.M., Yeh H.H., et al. Transcriptional activation of the Axl and PDGFR-alpha by c-Met through a ras- and Src-independent mechanism in human bladder cancer. BMC Cancer 2011, 11:139.
35. Li B., Kanamaru H., Noriki S., et al. Differential expression of hepatocyte growth factor in papillary and nodular tumors of the bladder. Int J Urol 1998, 5:436-440.
36. Ginty F., Adak S., Can A., et al. The relative distribution of membranous and cytoplasmic met is a prognostic indicator in stage I and II colon cancer. Clin Cancer Res 2008, 14:3814-3822.
37. Guo G., Sun X., Chen C., et al. Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation. Nat Genet 2013, 45:1459-1463.
38. Iyer G., Al-Ahmadie H., Schultz N., et al. Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer. JClin Oncol 2013, 31:3133-3140.
39. Nakazawa K., Dobashi Y., Suzuki S., et al. Amplification and overexpression of c-erbB-2, epidermal growth factor receptor, and c-met in biliary tract cancers. JPathol 2005, 206:356-365.
40. Smolen G.A., Sordella R., Muir B., et al. Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc Natl Acad Sci USA 2006, 103:2316-2321.
41. Zou H.Y., Li Q., Lee J.H., et al. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res 2007, 67:4408-4417.
42. Lynch T.J., Bell D.W., Sordella R., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. NEngl J Med 2004, 350:2129-2139.
43. Paez J.G., Janne P.A., Lee J.C., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304:1497-1500.
44. Pao W., Miller V., Zakowski M., et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004, 101:13306-13311.